Human recombinant DNA-derived antihemophilic factor in the treatment of previously untreated patients with hemophilia A: final report on a hallmark clinical investigation-Reference-Cited by-同舟云学术

Human recombinant DNA-derived antihemophilic factor in the treatment of previously untreated patients with hemophilia A: final report on a hallmark clinical investigation

Published:2004-04 Issue:4 Volume:2 Page:574-583
ISSN:1538-7933
Container-title:Journal of Thrombosis and Haemostasis
language:en
Short-container-title:J Thromb Haemost

Author:

Lusher J.,Abildgaard C.,Arkin S.,Mannucci P. M.,Zimmermann R.,Schwartz L.,Hurst D.

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1538-7933.2004.00646.x/fullpdf

Reference43 articles.

1. Hepatitis A Virus Transmission by Blood Products in the United States

2. Liver dysfunction in Pennsylvania's multitransfused hemophiliacs

3. EPIDEMIOLOGY OF HBV-ASSOCIATED DELTA AGENT: GEOGRAPHICAL DISTRIBUTION OF ANTI-DELTA AND PREVALENCE IN POLYTRANSFUSED HBsAg CARRIERS

4. Prevalence of hepatitis C virus antibody in a cohort of hemophilia patients [see comments]

Cited by 68 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. BAY 81-8973 Efficacy and Safety in Previously Untreated and Minimally Treated Children with Severe Hemophilia A: The LEOPOLD Kids Trial;Thrombosis and Haemostasis;2023-01

2. Secondary failure: immune responses to approved protein therapeutics;Trends in Molecular Medicine;2021-11

3. Immune Responses to Plasma-Derived Versus Recombinant FVIII Products;Frontiers in Immunology;2021-01-22

4. Epidemiological Challenges in Rare Bleeding Disorders: FVIII Inhibitor Incidence in Haemophilia A Patients—A Known Issue of Unknown Origin;International Journal of Environmental Research and Public Health;2020-12-30

5. Tailoring haemophilia A prophylaxis with BAY 81-8973: A case series;Transfusion and Apheresis Science;2020-12